维里西瓜特疗法与慢性心力衰竭的逆心肌重塑有关,减少了喷射分数
Tine Bajec1, Neža Žorž1, Sabina Ugovšek1
1Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
Journal of cardiovascular development and disease
|January 27, 2026
概括
添加到指南导向医学疗法 (GDMT) 的维里西瓜特显示出改善心脏功能和结构的承诺,在心力衰竭患者中减少排气分数 (HFrEF). 这项研究表明, vericiguat可能会促进最近恶化的HFrEF患者的逆心肌重塑.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 心脏衰竭研究研究
背景情况:
- 已知维里西瓜特可以减少最近恶化的心力衰竭与减少喷射率 (HFrEF) 的患者的心血管事件.
- vericiguat对这些患者心脏重塑的影响尚未完全理解.
研究的目的:
- 为了调查是否添加 vericiguat 准则导向医疗疗 (GDMT) 可以诱导反向心肌重塑在患有HFrEF和最近恶化的患者.
- 为了评估心脏结构和功能的变化后的治疗.
主要方法:
- 一个前性的,非随机的,单中心研究.
- 连续34名患有HFrEF和最近恶化,处于稳定的GDMT的患者被纳入.
- 临床,生化和心声学评估在基线和6个月后进行.
主要成果:
- 在右心室缩功能 (TAPSE) 和左心室外流通道速度-时间积分 (LVOT VTI) 中显著改善.
- 观察到右心室内部直径 (RVIDd) 和左心室末缩体积 (LVESV) 的减少,表明逆转重塑.
- 显著降低NT-proBNP水平,这是心力衰竭严重程度的标志物.
结论:
- 在患有HFrEF和最近恶化的患者中,向GDMT添加 vericiguat可能与心肌逆向重塑有关.
- 维里西瓜特通过改善心脏结构和功能,证明了除了减少主要心血管不良事件之外的潜在益处.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
313
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
313
01:17Pathophysiology of Heart Failure
3.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
01:27Heart Failure I: Introduction
829
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829
01:29Heart Failure II: Pathophysiology
855
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
855
01:22Heart Failure Drugs: Diuretics
935
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935
01:30Heart Failure V: Medical Management
267
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
267